优势价格
快速发货
品质保证
技术支持
400-920-2911 sales@csnpharm.cn
Cholecystokinin Receptor
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| CSN26386 | YM022 | 145084-28-2 | YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively[1]. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo[3]. |
| CSN22510 | Sograzepide | 155488-25-8 | Sograzepide is a gastrin/cholecystokinin 2 receptor (CCK2) antagonist. |
| CSN13775 | Rebamipide | 90098-04-7 | Rebamipide is an inducer of endogenous prostaglandin, an oxygen-derived free radical scavenger, and a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [125I]BH-CCK-8S with IC50 of 37.7 μM. |
| CSN23839 | Proglumide | 6620-60-6 | Proglumide is a known cholecystokinin (CCK) antagonist. |
| CSN11674 | Pentagastrin | 5534-95-2 | Pentagastrin (ICI-50123) is a selective agonist of Cholecystokinin B (CCKB) receptor with an IC50 of 11 nM. Pentagastrin is a synthetic polypeptide that has effects like gastrin when given parenterally, which can cause the secretion and synthesis of salivary proteins. |
| CSN18099 | Nastorazepide | 209219-38-5 | Nastorazepide is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. |
| CSN21716 | Loxiglumide | 107097-80-3 | Loxiglumide is a cholecystokinin (CCK) receptor antagonist. |
| CSN22513 | SR 146131 | 221671-61-0 | GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity. |
| CSN22411 | GI 181771 | 305366-98-7 | GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity. |
| CSN21655 | Gastrin I, human | 10047-33-3 | Gastrin I is an endogenous gastrointestinal peptide hormone that can bind to cholecystokinin (CCK) receptors. |
| CSN26412 | Devazepide | 103420-77-5 | Devazepide is a potent, competitive, selective and orally active nonpeptide antagonist of cholecystokinin (CCK) receptor, with IC50s of 81 pM, 45 pM and 245 nM for rat pancreatic, bovine gallbladder and guinea pig brain CCK receptors, respectively. Devazepide is effective for gastrointestinal disorders[1]. |
